Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3INDIV 2OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3Leukemia 3Myelodysplastic Syndromes 2Lymphoma 2Graft vs Host Disease 2Thymic aplasia 1Skin Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Erectile Dysfunction 1Dermatitis, Atopic 1Carcinoma, Non-Small-Cell Lung 1

Interventions

rozanolixizumab 10zilucoplan 7ravulizumab 7efgartigimod alfa 6eculizumab 5fludarabine 4Cyclophosphamide 4telitacicept 3Tacrolimus 3HBM9161 3inebilizumab 2Mycophenolic Acid 2Diagnostic Self Evaluation 2Amifampridine 2satralizumab 1rhoA GTP-Binding Protein 1remibrutinib 1iscalimab 1iptacopan 1Robotic Surgical Procedures 1Prednisone 1Prednisolone 1Plasmapheresis 1Immunoglobulins, Intravenous 1Data Collection 1Cladribine 1CK-2017357 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Myasthenia Gravis × Tacrolimus × Clear all
NCT01325571 2016-03-09

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis

Astellas Pharma Inc

Phase 3 Completed
83 enrolled

Myasthenia Gravis

NCT00309088 2014-08-25

FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients

Astellas Pharma Inc

Phase 3 Completed
80 enrolled

Myasthenia Gravis

NCT00309101 2009-06-03

An Open Study for Steroid Resistant, Non-Thymectomized MG Patients

Astellas Pharma Inc

Phase 3 Completed
11 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡